Cl-Amidine (trifluoroacetate salt): Selective PAD4 Inhibitor for Epigenetic and Disease Research

Executive Summary: Cl-Amidine (trifluoroacetate salt) is a crystalline small molecule that irreversibly inhibits protein arginine deiminase 4 (PAD4), blocking histone citrullination and modulating gene expression (Telerman et al., 2022). It demonstrates higher potency than F-amidine in PAD4 enzyme assays (IC₅₀ typically in the low micromolar range) under in vitro conditions. In murine models of cecal ligation and puncture (CLP)-induced septic shock, Cl-Amidine restores innate immune cell populations, attenuates pro-inflammatory cytokines, and improves survival outcomes. The compound is highly soluble in DMSO (≥20.55 mg/mL) and water (≥9.53 mg/mL with sonication), but insoluble in ethanol. APExBIO supplies Cl-Amidine (trifluoroacetate salt) as SKU C3829 for research use only (product page).

Biological Rationale

Protein arginine deiminase 4 (PAD4) is a calcium-dependent enzyme that catalyzes the conversion of arginine to citrulline on histone tails, a post-translational modification known as histone citrullination. This process alters chromatin structure and gene expression, impacting immune responses, cancer progression, and the formation of neutrophil extracellular traps (NETs) (Telerman et al., 2022). Dysregulated PAD4 activity has been implicated in the etiopathogenesis of rheumatoid arthritis, various cancers, and sepsis. Inhibition of the PAD4 enzyme reduces aberrant citrullination, limiting disease-associated gene expression and cellular phenotypes.

Mechanism of Action of Cl-Amidine (trifluoroacetate salt)

Cl-Amidine (trifluoroacetate salt) acts as an irreversible, covalent inhibitor of PAD4 by targeting the enzyme’s active site cysteine residue. This leads to the blockade of arginine deimination on histones, thereby suppressing the formation of citrullinated histones (notably H3cit) and downstream gene regulation events. The selectivity profile of Cl-Amidine has been characterized against PAD enzyme isoforms, with PAD4 inhibition displaying significantly higher potency compared to PAD2 and PAD3. In cellular models, Cl-Amidine treatment reduces NET formation, as measured by decreased H3cit and myeloperoxidase (MPO) expression, distinguishing its mode of action from inhibitors of reactive oxygen species (ROS) such as diphenyleneiodonium (DPI) (Telerman et al., 2022).

Evidence & Benchmarks

• Cl-Amidine at 100 μM inhibits PAD4-mediated citrullination and NET formation in BCR-ABL1-transduced HoxB8 neutrophil models, as shown by reduced H3cit and MPO levels (Telerman et al., 2022).
• In vitro, Cl-Amidine demonstrates dose-dependent inhibition of PAD4 enzyme activity with IC₅₀ values in the low micromolar range, outperforming F-amidine (EpigeneticsDomain.com).
• In CLP-induced septic shock mouse models, administration of Cl-Amidine results in improved survival, restoration of bone marrow and thymic cellularity, enhanced bacterial clearance, and reduced pro-inflammatory cytokines (APExBIO product data).
• Cl-Amidine is soluble at ≥20.55 mg/mL in DMSO and ≥9.53 mg/mL in water (ultrasound-assisted), but insoluble in ethanol, enabling flexible assay integration (APExBIO product data).
• The specificity of Cl-Amidine for PAD4 over other PAD isoforms has been confirmed in cellular and biochemical assays (Dibutyryl.com).

Applications, Limits & Misconceptions

Cl-Amidine (trifluoroacetate salt) is widely used in:

• Perturbing the protein arginine deimination pathway in epigenetic regulation studies.
• Mechanistic studies of cancer, rheumatoid arthritis, and inflammatory disease models where PAD4 activity is dysregulated.
• Assays investigating the formation of neutrophil extracellular traps (NETs) and their role in autoimmunity and thrombosis.
• In vivo models of sepsis, where PAD4 inhibition has been shown to restore immune cell populations and enhance survival.

This article extends the mechanistic and translational coverage found in "Cl-Amidine Trifluoroacetate Salt: Precision PAD4 Inhibition" by providing atomic, cross-validated data from recent peer-reviewed studies. For workflow guidance and troubleshooting, see "Cl-Amidine (trifluoroacetate salt): Reliable PAD4 Inhibition in Cell Assays", which focuses on reproducibility in cell-based contexts. For an advanced discussion of PAD4 in leukemia, consult "Cl-Amidine trifluoroacetate salt: PAD4 Inhibition in AML"; this article emphasizes generalizable parameters for diverse disease models.

Common Pitfalls or Misconceptions

• Cl-Amidine is not suitable as a PAD4 inhibitor in ethanol-based assays due to insolubility in ethanol.
• The compound is not intended for diagnostic or therapeutic use in humans; it is for research purposes only (APExBIO guidance).
• Long-term storage of dissolved Cl-Amidine solutions can result in reduced efficacy; stock solutions should be used promptly after preparation.
• PAD4-independent NETosis (e.g., ROS-only pathways) is not effectively blocked by Cl-Amidine, as shown by the lack of effect versus NADPH oxidase inhibitors (Telerman et al., 2022).
• Cl-Amidine may not fully inhibit PAD2 or PAD3 at concentrations optimized for PAD4, limiting its utility in studies targeting multiple PAD isoforms.

Workflow Integration & Parameters

Cl-Amidine (trifluoroacetate salt) is provided as a crystalline solid (molecular weight 424.8 g/mol) and should be stored at -20°C. For in vitro PAD4 enzyme activity assays, Cl-Amidine is typically dissolved in DMSO (≥20.55 mg/mL) or water (≥9.53 mg/mL, with sonication) to prepare stock solutions. Working concentrations range from 1–100 μM, depending on application and cell type. For in vivo murine studies, dosing parameters (e.g., mg/kg, injection route) should be referenced from published protocols or product technical sheets (APExBIO). Avoid repeated freeze-thaw cycles and prolonged exposure to room temperature. It is recommended to run PAD4 enzyme activity assays in parallel with vehicle controls and, when benchmarking selectivity, to include PAD2/PAD3 activity measurements. Workflow troubleshooting and best practices for cell-based and in vivo studies are detailed in the above-cited internal articles.

Conclusion & Outlook

Cl-Amidine (trifluoroacetate salt), available from APExBIO (SKU C3829), is an established, selective PAD4 inhibitor enabling precision studies in epigenetics, cancer, and immune regulation. Its robust inhibition of PAD4 activity and validated effects in both in vitro and in vivo models position it as a standard for mechanistic and translational research. Ongoing studies continue to expand its utility in complex disease modeling and drug discovery targeting the protein arginine deimination pathway.